Example ImageÃÀ¸ß÷

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞЧÀÍ×Éѯ £¬£¬ £¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
Customer Center
¿Í»§ÖÐÐÄ

»ªÈóË«º×˾ÃÀ¸ñ³ëÄ×¢ÉäÒº»ñÅúÁÙ´²

2024-04-16
|
»á¼ûÁ¿£º

΢ÐÅͼƬ_20240415171618.jpg

Ò½ÏßÒ©ÎÅ

1. 4ÔÂ15ÈÕ £¬£¬ £¬»ªÈóË«º×Ðû²¼Í¨¸æ³Æ £¬£¬ £¬ÆäÊÕµ½¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾ÖÇ©·¢µÄ˾ÃÀ¸ñ³ëÄ×¢ÉäÒº¡¶Ò©ÎïÁÙ´²ÊÔÑéÅú׼֪ͨÊé¡· £¬£¬ £¬ÊÊÓÃÓÚ³ÉÈË 2 ÐÍÌÇÄò²¡»¼ÕßµÄѪÌÇ¿ØÖÆ¡£¡£¡£ ¡£¡£¡£

2. 4ÔÂ15ÈÕ £¬£¬ £¬CDE¹ÙÍø¹«Ê¾ £¬£¬ £¬¸´ÐÇÒ½Ò©FCN-159ƬÄâÄÉÈëÓÅÏÈÉóÆÀ £¬£¬ £¬Õë¶Ô˳Ӧ֢ΪÖÎÁƳÉÈËÊ÷ͻ״ϸ°ûºÍ×é֯ϸ°ûÖ×Áö¡£¡£¡£ ¡£¡£¡£FCN-159ƬÊǸ´ÐÇÒ½Ò©Ñз¢µÄÒ»¿îMEK1/2Ñ¡ÔñÐÔÒÖÖÆ¼Á¡£¡£¡£ ¡£¡£¡£¸Ã²úÆ·´ËǰÒѾ­Á½´Î±»CDEÄÉÈëÍ»ÆÆÐÔÖÎÁÆÆ·ÖÖ¡£¡£¡£ ¡£¡£¡£

3. ¿ËÈÕ £¬£¬ £¬ºÍ¾¶Ò½Ò©¿Æ¼¼£¨ÉϺ££©ÓÐÏÞ¹«Ë¾ÐÂÒ»´úÕë¶ÔEGFRÍ»±äÍíÆÚ·ÇСϸ°û·Î°©µÄÂѰ×Ë®½â°ÐÏòǶºÏÌåHJ-002-03Õýʽ»ñµÃ¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾ÖÒ©Æ·ÉóÆÀÖÐÐÄ£¨CDE£©µÄÐÂÒ©ÁÙ´²ÊÔÑéÅú×¼¡£¡£¡£ ¡£¡£¡£

4. 4ÔÂ15ÈÕ £¬£¬ £¬°Ù³ÏÒ½Ò©Ðû²¼Í¨¸æ £¬£¬ £¬×ÔÖ÷Ñз¢µÄ2023HY252Ò©Æ·ÓÃÓÚ12Ëê¼°ÒÔÉÏñ²ðﻼÕß²¿·ÖÐÔ±¬·¢µÄ¼ÓÓÃÖÎÁƵÄÁÙ´²ÊÔÑéÒÑ»ñ¹ú¼ÒÒ©¼à¾ÖÅú×¼¡£¡£¡£ ¡£¡£¡£2023HY252ÊÇÒ»ÖÖ¿¹ñ²ðïÒ© £¬£¬ £¬ÊôÓÚßÁ¿©ÍéͪÑÜÉúÎï £¬£¬ £¬º£ÄÚÍâÉÐÎ޸òúÆ·»ñÅúÉÏÊС£¡£¡£ ¡£¡£¡£

ͶÈÚÒ©ÊÂ

1. ¿ËÈÕ £¬£¬ £¬ÆÕÂåÒ©ÒµÐû²¼Í¨¸æ³Æ £¬£¬ £¬¹«Ë¾ÓëÕã½­ºÍÔóÒ½Ò©¿Æ¼¼¹É·ÝÓÐÏÞ¹«Ë¾±¾×ÅÓÅÊÆ»¥²¹¡¢»¥»Ý»¥Àû¡¢Ð­Í¬Á¢Òì¡¢ÅäºÏÉú³¤µÄÔ­Ôò £¬£¬ £¬½¨Éè²¢Éú³¤Õ½ÂÔÏàÖú¹ØÏµ£»£»£» £»£»£»Ë«·½½«Î§ÈÆÒ©Æ·Ñз¢¼¼ÊõЧÀÍ¡¢Ò©Æ·Éú²ú¼Ó¹¤ºÍÒ©Æ·Êг¡ÍƹãµÈÁìÓòÕö¿ªÓªÒµÏàÖú¡¢ÊµÏÖ¹²Ó® £¬£¬ £¬²¢ÓÚ¿ËÈÕÇ©ÊðÁË¡¶Õ½ÂÔÏàÖú¿ò¼ÜЭÒé¡·¡£¡£¡£ ¡£¡£¡£

¿Æ¼¼Ò©ÑÐ

1. 4ÔÂ15ÈÕ £¬£¬ £¬µ¤ÄÈ-·¨²®°©Ö¢Ñо¿ËùºÍ¹þ·ðҽѧԺµÄŵ½±µÃÖ÷ William G. Kaelin Jr. ¼°ÆäÍŶÓÔÚ Cell ½ÒÏþÁËÌâΪ Positive selection CRISPR screens and cryo-EM reveal a druggable pocket in an oligosaccharyltransferase required for inflammatory signaling to NF-kB µÄÑо¿ÂÛÎÄ £¬£¬ £¬ËûÃÇʹÓà CRISPR ɸѡ¼¼ÊõºÍÀä¶³µç¾µ¼¼Êõ £¬£¬ £¬Õ¹ÏÖÁËÒ»ÖÖÔÚ NF-kB ÐźÅͨ·ÖÐÆð×÷ÓõÄÒ©Îï°Ðµã¡£¡£¡£ ¡£¡£¡£

[1]Lampson et al., Positive selection CRISPR screens and cryo-EM reveal a druggable pocket in an oligo-saccharyltransferase required for inflammatory signaling to NF-kB, Cell (2024).

Ïà¹ØÐÂÎÅ
ÃÀ¸ß÷ÖúÁ¦ÖÊëÄÉúÎï˾ÃÀ¸ñ³ëÄ×¢ÉäÒºÁÙ´²ÉêÇë»ñCDEÊÜÀí£»£»£» £»£»£»ÍƽøZT002ÖС¢ÃÀ¡¢°ÄÈý±¨
2022-11-04
×÷ΪÖÊëÄÉúÎïµÄÏàÖúͬ°é £¬£¬ £¬ÃÀ¸ß÷£¨ÒÔϼò³Æ¡°ÃÀ¸ß÷£©ÎªÖÊëÄÉúÎï˾ÃÀ¸ñ³ëÄ×¢ÉäÒºÌṩÁËÈ«Ì×ÁÙ´²Ç°Ñо¿Ð§ÀÍ £¬£¬ £¬ÎªÖÊëÄÉúÎïZT002ÌṩÁËÇкÏÖС¢ÃÀ¡¢°ÄÈý¹úÉ걨µÄҩЧЧÀÍ £¬£¬ £¬¼ÓËÙÁËÍâÑóÁÙ´²É걨Àú³Ì¡£¡£¡£ ¡£¡£¡£
»ª¶«Ò½Ò©Ë¾ÃÀ¸ñ³ëÄ×¢ÉäÒºIIIÆÚÁÙ´²ÊÔÑéÍê³ÉÊ×ÀýÊÜÊÔÕßÈë×é¼°¸øÒ©
2023-09-21
9ÔÂ21ÈÕ»ñϤ £¬£¬ £¬»ª¶«Ò½Ò©È«×Ê×Ó¹«Ë¾º¼ÖÝÖÐÃÀ»ª¶«ÖÆÒ©ÓÐÏÞ¹«Ë¾ºÍÖØÇìÅɽðÉúÎï¿Æ¼¼ÓÐÏÞ¹«Ë¾ £¬£¬ £¬ÅäºÏ¿ªÕ¹µÄ˾ÃÀ¸ñ³ëÄ×¢ÉäÒºIIIÆÚÁÙ´²ÊÔÑéÍê³ÉÊ×ÀýÊÜÊÔÕßÈë×é¼°¸øÒ©¡£¡£¡£ ¡£¡£¡£¸ÃÑо¿ÊÇÒ»Ïî¶àÖÐÐÄ¡¢Ëæ»ú¡¢¿ª·Å¡¢Æ½ÐбÈÕÕµÄIIIÆÚÁÙ´²Ñо¿ £¬£¬ £¬Ö÷ҪĿµÄÊÇÔÚ¶þ¼×Ë«ëÒÖÎÁƺóѪÌÇ¿ØÖƲ»¼ÑµÄ2ÐÍÌÇÄò²¡»¼ÕßÖÐÂÛÖ¤ÊÔÑéÒ©Îï˾ÃÀ¸ñ³ëÄ×¢ÉäÒºÓë±ÈÕÕÒ©Îï˾ÃÀ¸ñ³ëÄ×¢ÉäÒº£¨ÅµºÍÌ©?£©ÔÚÖÎÁÆ32ÖܺóѪÌÇ¿ØÖƵĵÈЧÐÔ¡£¡£¡£ ¡£¡£¡£
ÀöÖ鼯ÍÅ˾ÃÀ¸ñ³ëÄ×¢ÉäÒº»ñÒ©ÎïÁÙ´²ÊÔÑéÅú×¼
2024-02-06
2ÔÂ5ÈÕ £¬£¬ £¬ÀöÖ鼯ÍÅÐû²¼Í¨¸æ³Æ £¬£¬ £¬¹«Ë¾¿Ø¹ÉÁ¥Êô¹«Ë¾ÀöÖ鼯ÍÅб±½­ÖÆÒ©¹É·ÝÓÐÏÞ¹«Ë¾ÊÕµ½¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾ÖÅú׼ǩ·¢µÄ¡¶Ò©ÎïÁÙ´²ÊÔÑéÅú׼֪ͨÊé¡· £¬£¬ £¬Åú׼˾ÃÀ¸ñ³ëÄ×¢ÉäÒº°´ÉúÎïÀàËÆÒ©µÄ¼¼ÊõÒªÇó¿ªÕ¹ÌåÖØ¹ÜÀí˳Ӧ֢ÁÙ´²ÊÔÑé¡£¡£¡£ ¡£¡£¡£
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿